Article Text

PDF

Quinolone derivative, flumequine, as short-term treatment for gonorrhoea.
  1. H B Svindland,
  2. P L Svarva,
  3. J A Maeland

    Abstract

    The antigonococcal activity of the quinolone derivative flumequine was evaluated. Of 246 strains examined, 240 (97.5%) strains showed minimum inhibitory concentrations (MICs) of flumequine of less than or equal to 0.4 microgram/ml, including three beta-lactamase-producing strains. The six remaining strains showed MICs from 3.2 to 9.6 micrograms/ml. By disc diffusion tests using 3-micrograms discs of flumequine the zones of growth inhibition correlated well with the MICs of flumequine. The effect of treatment with flumequine was compared in 239 patients with uncomplicated gonorrhoea. A single dose regimen of 1200 mg flumequine orally, a two-dose regimen of 1200 and 800 mg, and a three-dose regimen of 1200, 800, and 800 mg (six hours apart) were given. With a single dose of flumequine the failure rate was 26%. The two-dose and three-dose regimens were equally effective with an overall cure rate of 95.4%. In patients harbouring beta-lactamase-producing gonococci the infection was cured. The failures (10 men) included all of the six patients infected with flumequine-resistant gonococci. Side effects were noted by 14.6% of the patients and were mostly described as dizziness.

    Statistics from Altmetric.com

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.